Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 130

1.

Controlled human infection for vaccination against Streptococcus pyogenes (CHIVAS): Establishing a group A Streptococcus pharyngitis human infection study.

Osowicki J, Azzopardi KI, Baker C, Waddington CS, Pandey M, Schuster T, Grobler A, Cheng AC, Pollard AJ, McCarthy JS, Good MF, Walker MJ, Dale JB, Batzloff MR, Carapetis JR, Smeesters PR, Steer AC.

Vaccine. 2019 Jun 6;37(26):3485-3494. doi: 10.1016/j.vaccine.2019.03.059. Epub 2019 May 14.

PMID:
31101422
2.

Development of an Opsonophagocytic Killing Assay Using HL-60 Cells for Detection of Functional Antibodies against Streptococcus pyogenes.

Salehi S, Hohn CM, Penfound TA, Dale JB.

mSphere. 2018 Dec 19;3(6). pii: e00617-18. doi: 10.1128/mSphere.00617-18.

3.

Clinical and microbiological response of mice to intranasal inoculation with Lactococcus lactis expressing Group A Streptococcus antigens, to be used as an anti-streptococcal vaccine.

García PC, Paillavil BA, Scioscia N, Dale JB, Legarraga P, Salazar-Echegarai FJ, Bueno SM, Kalergis AM, Wozniak A.

Microbiol Immunol. 2018 Nov;62(11):711-719. doi: 10.1111/1348-0421.12657.

PMID:
30357922
4.

Caution Indicated in Extrapolating Carditis in Rats to Rheumatic Heart Disease in Humans.

Dale JB, Shulman ST.

J Infect Dis. 2019 Jan 29;219(4):674-675. doi: 10.1093/infdis/jiy560. No abstract available.

PMID:
30247730
5.

Group A Streptococcal Virulence: New Lessons.

Shulman ST, Dale JB.

J Pediatric Infect Dis Soc. 2019 May 11;8(2):160-161. doi: 10.1093/jpids/piy059. No abstract available.

PMID:
29982621
6.

Blocking Neuronal Signaling to Immune Cells Treats Streptococcal Invasive Infection.

Pinho-Ribeiro FA, Baddal B, Haarsma R, O'Seaghdha M, Yang NJ, Blake KJ, Portley M, Verri WA, Dale JB, Wessels MR, Chiu IM.

Cell. 2018 May 17;173(5):1083-1097.e22. doi: 10.1016/j.cell.2018.04.006. Epub 2018 May 10.

7.

Protective immunity induced by an intranasal multivalent vaccine comprising 10 Lactococcus lactis strains expressing highly prevalent M-protein antigens derived from Group A Streptococcus.

Wozniak A, Scioscia N, García PC, Dale JB, Paillavil BA, Legarraga P, Salazar-Echegarai FJ, Bueno SM, Kalergis AM.

Microbiol Immunol. 2018 Jun;62(6):395-404. doi: 10.1111/1348-0421.12595. Epub 2018 Jun 11.

8.

Immune Cross-Opsonization Within emm Clusters Following Group A Streptococcus Skin Infection: Broadening the Scope of Type-Specific Immunity.

Frost HR, Laho D, Sanderson-Smith ML, Licciardi P, Donath S, Curtis N, Kado J, Dale JB, Steer AC, Smeesters PR.

Clin Infect Dis. 2017 Oct 16;65(9):1523-1531. doi: 10.1093/cid/cix599.

PMID:
29020160
9.

Prospective Longitudinal Analysis of Immune Responses in Pediatric Subjects After Pharyngeal Acquisition of Group A Streptococci.

Hysmith ND, Kaplan EL, Cleary PP, Johnson DR, Penfound TA, Dale JB.

J Pediatric Infect Dis Soc. 2017 Jun 1;6(2):187-196. doi: 10.1093/jpids/piw070.

PMID:
28204534
10.

Trivalent M-related protein as a component of next generation group A streptococcal vaccines.

Courtney HS, Niedermeyer SE, Penfound TA, Hohn CM, Greeley A, Dale JB.

Clin Exp Vaccine Res. 2017 Jan;6(1):45-49. doi: 10.7774/cevr.2017.6.1.45. Epub 2017 Jan 25.

11.

Structure-based design of broadly protective group a streptococcal M protein-based vaccines.

Dale JB, Smeesters PR, Courtney HS, Penfound TA, Hohn CM, Smith JC, Baudry JY.

Vaccine. 2017 Jan 3;35(1):19-26. doi: 10.1016/j.vaccine.2016.11.065. Epub 2016 Nov 24.

12.

The Cape Town Clinical Decision Rule for Streptococcal Pharyngitis in Children.

Engel ME, Cohen K, Gounden R, Kengne AP, Barth DD, Whitelaw AC, Francis V, Badri M, Stewart A, Dale JB, Mayosi BM, Maartens G.

Pediatr Infect Dis J. 2017 Mar;36(3):250-255. doi: 10.1097/INF.0000000000001413.

13.

One More Disguise in the Stealth Behavior of Streptococcus pyogenes.

Fischetti VA, Dale JB.

MBio. 2016 May 17;7(3). pii: e00661-16. doi: 10.1128/mBio.00661-16.

14.

Status of research and development of vaccines for Streptococcus pyogenes.

Steer AC, Carapetis JR, Dale JB, Fraser JD, Good MF, Guilherme L, Moreland NJ, Mulholland EK, Schodel F, Smeesters PR.

Vaccine. 2016 Jun 3;34(26):2953-2958. doi: 10.1016/j.vaccine.2016.03.073. Epub 2016 Mar 29.

15.

Current Approaches to Group A Streptococcal Vaccine Development.

Dale JB, Batzloff MR, Cleary PP, Courtney HS, Good MF, Grandi G, Halperin S, Margarit IY, McNeil S, Pandey M, Smeesters PR, Steer AC.

In: Ferretti JJ, Stevens DL, Fischetti VA, editors. Streptococcus pyogenes : Basic Biology to Clinical Manifestations [Internet]. Oklahoma City (OK): University of Oklahoma Health Sciences Center; 2016-.
2016 Feb 10.

16.

Protective immunogenicity of group A streptococcal M-related proteins.

Dale JB, Niedermeyer SE, Agbaosi T, Hysmith ND, Penfound TA, Hohn CM, Pullen M, Bright MI, Murrell DS, Shenep LE, Courtney HS.

Clin Vaccine Immunol. 2015 Mar;22(3):344-50. doi: 10.1128/CVI.00795-14. Epub 2015 Jan 28.

17.

Streptococcal pharyngitis in schoolchildren in Bamako, Mali.

Tapia MD, Sow SO, Tamboura B, Keita MM, Berthe A, Samake M, Nataro JP, Onwuchekwa UO, Penfound TA, Blackwelder W, Dale JB, Kotloff KL.

Pediatr Infect Dis J. 2015 May;34(5):463-8. doi: 10.1097/INF.0000000000000608.

18.

In memoriam: Gene H. Stollerman.

Dale JB, Bisno AL.

Clin Infect Dis. 2014 Dec 15;59(12):1805-6. doi: 10.1093/cid/ciu718. Epub 2014 Sep 8. No abstract available.

PMID:
25205767
19.

Added value of the emm-cluster typing system to analyze group A Streptococcus epidemiology in high-income settings.

Shulman ST, Tanz RR, Dale JB, Steer AC, Smeesters PR.

Clin Infect Dis. 2014 Dec 1;59(11):1651-2. doi: 10.1093/cid/ciu649. Epub 2014 Aug 12. No abstract available.

20.

Group A streptococcus expresses a trio of surface proteins containing protective epitopes.

Niedermeyer SE, Penfound TA, Hohn C, Li Y, Homayouni R, Zhao J, Dale JB.

Clin Vaccine Immunol. 2014 Oct;21(10):1421-5. doi: 10.1128/CVI.00448-14. Epub 2014 Jul 30.

21.

Vaccination against the M protein of Streptococcus pyogenes prevents death after influenza virus: S. pyogenes super-infection.

Klonoski JM, Hurtig HR, Juber BA, Schuneman MJ, Bickett TE, Svendsen JM, Burum B, Penfound TA, Sereda G, Dale JB, Chaussee MS, Huber VC.

Vaccine. 2014 Sep 8;32(40):5241-9. doi: 10.1016/j.vaccine.2014.06.093. Epub 2014 Jul 29.

22.

A novel live vector group A streptococcal emm type 9 vaccine delivered intranasally protects mice against challenge infection with emm type 9 group A streptococci.

Wozniak A, García P, Geoffroy EA, Aguirre DB, González SA, Sarno VA, Dale JB, Salazar-Echegarai FJ, Vera A, Bueno SM, Kalergis AM.

Clin Vaccine Immunol. 2014 Sep;21(9):1343-9. doi: 10.1128/CVI.00330-14. Epub 2014 Jul 23.

23.

A systematic and functional classification of Streptococcus pyogenes that serves as a new tool for molecular typing and vaccine development.

Sanderson-Smith M, De Oliveira DM, Guglielmini J, McMillan DJ, Vu T, Holien JK, Henningham A, Steer AC, Bessen DE, Dale JB, Curtis N, Beall BW, Walker MJ, Parker MW, Carapetis JR, Van Melderen L, Sriprakash KS, Smeesters PR; M Protein Study Group.

J Infect Dis. 2014 Oct 15;210(8):1325-38. doi: 10.1093/infdis/jiu260. Epub 2014 May 5.

24.

Group A streptococcal emm type prevalence among symptomatic children in Cape Town and potential vaccine coverage.

Engel ME, Muhamed B, Whitelaw AC, Musvosvi M, Mayosi BM, Dale JB.

Pediatr Infect Dis J. 2014 Feb;33(2):208-10. doi: 10.1097/INF.0b013e3182a5c32a.

25.

Group A streptococcal vaccines: paving a path for accelerated development.

Dale JB, Fischetti VA, Carapetis JR, Steer AC, Sow S, Kumar R, Mayosi BM, Rubin FA, Mulholland K, Hombach JM, Schödel F, Henao-Restrepo AM.

Vaccine. 2013 Apr 18;31 Suppl 2:B216-22. doi: 10.1016/j.vaccine.2012.09.045. Review.

PMID:
23598485
26.

Potential coverage of a multivalent M protein-based group A streptococcal vaccine.

Dale JB, Penfound TA, Tamboura B, Sow SO, Nataro JP, Tapia M, Kotloff KL.

Vaccine. 2013 Mar 15;31(12):1576-81. doi: 10.1016/j.vaccine.2013.01.019. Epub 2013 Jan 31.

27.

Progress toward a global group a streptococcal vaccine.

Steer AC, Dale JB, Carapetis JR.

Pediatr Infect Dis J. 2013 Feb;32(2):180-2. doi: 10.1097/INF.0b013e318281da11. No abstract available.

PMID:
23328823
28.

New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococci.

Dale JB, Penfound TA, Chiang EY, Walton WJ.

Vaccine. 2011 Oct 26;29(46):8175-8. doi: 10.1016/j.vaccine.2011.09.005. Epub 2011 Sep 13.

29.

Progress in the development of effective vaccines to prevent selected gram-positive bacterial infections.

Bronze MS, Dale JB.

Am J Med Sci. 2010 Sep;340(3):218-25. doi: 10.1097/MAJ.0b013e3181e939ab. Review.

30.

Protective efficacy of group A streptococcal vaccines containing type-specific and conserved M protein epitopes.

Penfound TA, Chiang EY, Ahmed EA, Dale JB.

Vaccine. 2010 Jul 12;28(31):5017-22. doi: 10.1016/j.vaccine.2010.05.018. Epub 2010 May 21.

31.

Prevalence of rheumatic heart disease in children and young adults in Nicaragua.

Paar JA, Berrios NM, Rose JD, Cáceres M, Peña R, Pérez W, Chen-Mok M, Jolles E, Dale JB.

Am J Cardiol. 2010 Jun 15;105(12):1809-14. doi: 10.1016/j.amjcard.2010.01.364. Epub 2010 Apr 27.

32.

The NH(2)-terminal region of Streptococcus pyogenes M5 protein confers protection against degradation by proteases and enhances mucosal colonization of mice.

Penfound TA, Ofek I, Courtney HS, Hasty DL, Dale JB.

J Infect Dis. 2010 May 15;201(10):1580-8. doi: 10.1086/652005.

33.

Streptococcal protective antigens (Spa): a new family of type-specific proteins of group A streptococci.

Ahmed EA, Penfound TA, Brewer SC, Tennant PA, Chiang EY, Dale JB.

Eur J Clin Microbiol Infect Dis. 2010 Jan;29(1):51-7. doi: 10.1007/s10096-009-0819-0. Epub 2009 Oct 29.

PMID:
19865839
34.

Seven-year surveillance of north american pediatric group a streptococcal pharyngitis isolates.

Shulman ST, Tanz RR, Dale JB, Beall B, Kabat W, Kabat K, Cederlund E, Patel D, Rippe J, Li Z, Sakota V; North American Streptococcal Pharyngitis Surveillance Group.

Clin Infect Dis. 2009 Jul 1;49(1):78-84. doi: 10.1086/599344.

PMID:
19480575
35.

Inactivation of DltA modulates virulence factor expression in Streptococcus pyogenes.

Cox KH, Ruiz-Bustos E, Courtney HS, Dale JB, Pence MA, Nizet V, Aziz RK, Gerling I, Price SM, Hasty DL.

PLoS One. 2009;4(4):e5366. doi: 10.1371/journal.pone.0005366. Epub 2009 Apr 29.

36.

Relationship between expression of the family of M proteins and lipoteichoic acid to hydrophobicity and biofilm formation in Streptococcus pyogenes.

Courtney HS, Ofek I, Penfound T, Nizet V, Pence MA, Kreikemeyer B, Podbielski A, Hasty DL, Dale JB.

PLoS One. 2009;4(1):e4166. doi: 10.1371/journal.pone.0004166. Epub 2009 Jan 9. Erratum in: PLoS ONE. 2009;28(2). doi: 10.1371/annotation/823215e6-c06a-4d5f-ac7b-0ee77067ccb2. PLoS ONE. 2009;4(1). doi: 10.1371/annotation/c2f3e4e5-b6a0-4be8-9f8c-3d4e01933385. Podbielbski, Andreas [corrected to Podbielski, Andreas].

37.

Age-associated differences in prevalence of group A streptococcal type-specific M antibodies in children.

Jaggi P, Dale JB, Chiang E, Beniwal P, Kabat W, Shulman ST.

Eur J Pediatr. 2009 Jun;168(6):679-83. doi: 10.1007/s00431-008-0819-6. Epub 2008 Sep 24.

PMID:
18813950
38.

The importance of the group a streptococcus capsule in the pathogenesis of human infections: a historical perspective.

Stollerman GH, Dale JB.

Clin Infect Dis. 2008 Apr 1;46(7):1038-45. doi: 10.1086/529194. Review.

PMID:
18444821
39.

Current status of group A streptococcal vaccine development.

Dale JB.

Adv Exp Med Biol. 2008;609:53-63. doi: 10.1007/978-0-387-73960-1_5. Review.

PMID:
18193657
40.

Temporal changes in streptococcal M protein types and the near-disappearance of acute rheumatic fever in the United States.

Shulman ST, Stollerman G, Beall B, Dale JB, Tanz RR.

Clin Infect Dis. 2006 Feb 15;42(4):441-7. Epub 2006 Jan 17.

PMID:
16421785
41.

Anti-phagocytic mechanisms of Streptococcus pyogenes: binding of fibrinogen to M-related protein.

Courtney HS, Hasty DL, Dale JB.

Mol Microbiol. 2006 Feb;59(3):936-47.

42.

Prospects for a group A streptococcal vaccine: rationale, feasibility, and obstacles--report of a National Institute of Allergy and Infectious Diseases workshop.

Bisno AL, Rubin FA, Cleary PP, Dale JB; National Institute of Allergy and Infectious Diseases.

Clin Infect Dis. 2005 Oct 15;41(8):1150-6. Epub 2005 Sep 2.

PMID:
16163634
43.

Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers.

McNeil SA, Halperin SA, Langley JM, Smith B, Warren A, Sharratt GP, Baxendale DM, Reddish MA, Hu MC, Stroop SD, Linden J, Fries LF, Vink PE, Dale JB.

Clin Infect Dis. 2005 Oct 15;41(8):1114-22. Epub 2005 Sep 12.

PMID:
16163629
44.

Multivalent group A streptococcal vaccine elicits bactericidal antibodies against variant M subtypes.

Dale JB, Penfound T, Chiang EY, Long V, Shulman ST, Beall B.

Clin Diagn Lab Immunol. 2005 Jul;12(7):833-6.

45.

Group A streptococcal pharyngitis serotype surveillance in North America, 2000-2002.

Shulman ST, Tanz RR, Kabat W, Kabat K, Cederlund E, Patel D, Li Z, Sakota V, Dale JB, Beall B; US Streptococcal Pharyngitis Surveillance Group.

Clin Infect Dis. 2004 Aug 1;39(3):325-32. Epub 2004 Jul 15.

PMID:
15306998
46.

Safety and immunogenicity of a recombinant multivalent group a streptococcal vaccine in healthy adults: phase 1 trial.

Kotloff KL, Corretti M, Palmer K, Campbell JD, Reddish MA, Hu MC, Wasserman SS, Dale JB.

JAMA. 2004 Aug 11;292(6):709-15.

PMID:
15304468
47.

Progress in group A streptococcal vaccine development.

Kotloff KL, Dale JB.

Pediatr Infect Dis J. 2004 Aug;23(8):765-6. Review. No abstract available.

PMID:
15295227
48.

Intranasal immunization with multivalent group A streptococcal vaccines protects mice against intranasal challenge infections.

Hall MA, Stroop SD, Hu MC, Walls MA, Reddish MA, Burt DS, Lowell GH, Dale JB.

Infect Immun. 2004 May;72(5):2507-12.

50.

Southern Society for Clinical Investigation Founders' Medal recipient's address.

Dale JB.

Am J Med Sci. 2002 Aug;324(2):61-6. No abstract available.

PMID:
12186108

Supplemental Content

Support Center